ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Cronos Group's annualizedNet Income for the quarter that ended in Mar. 2026 was $55.0 Mil.
Cronos Group's average Total Assets over the quarter that ended in Mar. 2026 was $1,184.6 Mil. Therefore, Cronos Group's annualized ROA % for the quarter that ended in Mar. 2026 was 4.64%.
The historical rank and industry rank for Cronos Group's ROA % or its related term are showing as below:
CRON'
s ROA % Range Over the Past 10 Years
Min: -23.83 Med: -3.86 Max: 102.43
Current: -0.12
During the past 12 years, Cronos Group's highest ROA % was 102.43%. The lowest was -23.83%. And the median was -3.86%.
CRON's ROA % is ranked worse than 63.61% of 1003
companies
in the Drug Manufacturers industry
Industry Median: 2.69
vs CRON: -0.12
Cronos Group (NAS:CRON) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Cronos Group ROA % Related Terms
Cronos Group ROA % Historical Data
* Premium members only.
The historical data trend for Cronos Group's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cronos Group's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cronos Group ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cronos Group's ROA % distribution charts can be found below:
* The bar in red indicates where Cronos Group's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Cronos Group (CRON) has a ROA % of 4.64% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Cronos Group and its competitors. According to the industry distribution chart, Cronos Group ranks #638 out of 1003 companies in the Drug Manufacturers industry, placing it in the top 63.6%.
Is Cronos Group's ROA % too high?
Cronos Group's current ROA % is 4.64%. The Drug Manufacturers industry median ROA % is 2.69. Cronos Group's value of 4.64% is 72.5% above this industry median. Based on the distribution chart, Cronos Group ranks #638 out of 1003 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cronos Group has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cronos Group's ROA % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cronos Group ranks #638 out of 1003 companies for ROA %. This places Cronos Group in the lower half of its industry. The industry median ROA % is 2.69. Cronos Group's value of 4.64% is 72.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.69, based on 1,003 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cronos Group's current ROA % of 4.64% is 72.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Cronos Group and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cronos Group's current ROA % is 4.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cronos Group stock overvalued right now?
Based on GuruFocus' analysis, Cronos Group (CRON) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.49, compared to a current price of $2.82 — trading 19.2% below its estimated fair value. The current ROA % is 4.64% and 72.5% above the Drug Manufacturers industry median of 2.69. Cronos Group's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Cronos Group (CRON), the current ROA % is 4.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cronos Group (CRON) Overvalued in 2026?
Based on GuruFocus' analysis, Cronos Group stock appears to be undervalued.
The current stock price of $2.82 is trading 19.2% below its estimated GF Value™ of $3.49.
GuruFocus considers Cronos Group to be Modestly Undervalued.
Key valuation signals for CRON:
ROA %: 4.64%
GF Value™: $3.49 vs. price of $2.82 (19.2% below fair value)
Industry Position: 72.5% above the Drug Manufacturers median (#638 of 1003)
No single metric tells the full story. See the CRON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
86GF Score
Get the complete analysis for CRON
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRON has been successfully added to your 
